^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD3 agonist

    Related drugs:
    1d
    XmAb819-01: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=307, Recruiting, Xencor, Inc. | N=95 --> 307 | Trial completion date: Nov 2027 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Enrollment change • Trial completion date • Trial primary completion date
    1d
    SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jan 2027
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
    1d
    Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, Fondazione Italiana Linfomi - ETS
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Columvi (glofitamab-gxbm)
    1d
    A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=41, Recruiting, Jennifer Crombie, MD | Active, not recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    1d
    Low Dose Epcoritamab Plus GemOx in R/R DLBCL (clinicaltrials.gov)
    P2, N=10, Recruiting, Hospital Universitario Dr. Jose E. Gonzalez
    New P2 trial
    |
    gemcitabine • oxaliplatin • Epkinly (epcoritamab-bysp)
    2d
    Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement. (PubMed, Front Oncol)
    Preliminary reports indicate that the monoclonal antibody glofitamab can penetrate the blood-brain barrier, inducing clinical responses in CNS DLBCL patients by activating T lymphocytes. This report presents preliminary clinical evidence on the use of glofitamab in HIV-positive patients with secondary CNS lymphoma.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Columvi (glofitamab-gxbm)
    2d
    HAP2HCT: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, St. Jude Children's Research Hospital | N=140 --> 69 | Trial completion date: Aug 2025 --> Jun 2026
    Enrollment change • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • WT1 (WT1 Transcription Factor) • CREBBP (CREB binding protein) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A) • KDM5A (Lysine Demethylase 5A) • DEK (DEK Proto-Oncogene) • AFDN (Afadin, Adherens Junction Formation Factor) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    FLT3-ITD mutation
    |
    cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    2d
    A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy (clinicaltrials.gov)
    P2, N=17, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Talvey (talquetamab-tgvs)
    2d
    CLN-978-SJ-101: A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogrens Disease (2025-521462-96-00)
    P1, N=30, Recruiting, Cullinan Therapeutics Inc.
    New P1 trial
    |
    CLN-978
    3d
    AUDAX: A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia (clinicaltrials.gov)
    P3, N=560, Not yet recruiting, Amgen | Trial completion date: Mar 2033 --> Aug 2033 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Dec 2029 --> May 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Blincyto (blinatumomab)
    3d
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Novartis Pharmaceuticals | N=140 --> 61
    Enrollment change
    |
    CD19 positive
    |
    PIT565
    3d
    DeLLphi-309: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (clinicaltrials.gov)
    P2, N=252, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imdelltra (tarlatamab-dlle)